CEACAM1 and head and neck squamous cell carcinoma: Blocking CEACAM1 using targeted antibodies or small molecules may restore the body’s anti-tumor immunity and represents a promising new immunotherapy approach for head and neck squamous cell carcinoma (HNSCC) (Tsang et al., 2022).